It’s not the fittest or the most intelligent, it’s those who are most willing to adapt to change that will survive.
OXGENE, the new trading name of Oxford Genetics Ltd
OXGENE find solutions to seemingly impossible problems. We develop new technologies in mammalian cell engineering along the whole spectrum from discovery science to engineering at scale. Our unique combination of precision engineering and breakthrough science with advanced robotics and bioinformatics accelerates the rational design, manufacture and processing of complex biologics.
We work at the very edge of impossible to solve the problem of high titre virus manufacture for gene therapy treatments. We do this with high titre, high-quality, suspension transient viral manufacturing systems, AAV and lentiviral packaging and producer cell lines. We address the challenge of speed and consistency in gene editing with our high throughput automated CRISPR platform, and we deliver the breakthrough needed to discover antibodies to membrane proteins through novel mammalian display techniques.
We work to redefine ‘possible’ in mammalian cell engineering.
OXGENE accelerates therapy discovery and production, while lowering the cost to manufacturers and patients.
We offer our expertise for custom projects to solve challenges in the advancement of drug discovery and development, and we collaborate to bring new solutions to market faster and more efficiently.
Our licensable platform technologies are an essential element of our portfolio and we work hard to grow this to bring the robust tools needed to advance drug validation to market.
Our customers value our ability to come up with bespoke solutions. Our scientists are experts in their field and invest time in understanding the challenge and priorities that shape a custom project. We continue to support our customers throughout solution design and project delivery, as well as through any technology transfer.
Our investment in automation means we can provide repeatable solutions to some of the most complex processes in the industry today.